Status:

COMPLETED

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

Lead Sponsor:

BioMarin Pharmaceutical

Conditions:

Phenylketonurias

Eligibility:

All Genders

8+ years

Phase:

PHASE3

Brief Summary

The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.

Eligibility Criteria

Inclusion

  • 8 years of age and older
  • Prior successful participation in Study PKU-003
  • Willing and able to provide written informed consent or assent and written informed consent (if required) by a parent or legal guardian
  • For females of child-bearing potential only: Negative urine pregnancy test within 24 hours prior to enrollment. Women using acceptable birth control measures must agree to continue to use those measures while participating in the study
  • Willing and able to comply with study procedures
  • Willing to continue current diet unchanged while participating in the study

Exclusion

  • Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable
  • Withdrew from, or otherwise did not successfully complete, study PKU-003, except for subjects who were removed from the study because their blood Phe exceeded the alert level
  • Expected to require any investigational agent or vaccine prior to completion of all scheduled study assessments
  • Pregnant or breastfeeding, or planning pregnancy
  • Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
  • Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)
  • Concurrent use of levodopa

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

End Date :

June 1 2006

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00225615

Start Date

November 1 2005

End Date

June 1 2006

Last Update

August 20 2009

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Los Angeles, California, United States

2

Oakland, California, United States

3

Sacramento, California, United States

4

San Jose, California, United States